Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 1;107(6):1454-1459.
doi: 10.3324/haematol.2021.280026.

A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia

Milena Kohn  1 , Marc Delord  2 , Maureen Chbat  1 , Amina Guemriche  1 , Fatiha Merabet  1 , Anne-Laure Roupie  1 , Naelle Lombion  3 , Hassan Farhat  1 , Thomas Longval  1 , Aurélie Cabannes-Hamy  1 , Juliette Lambert  1 , Stéphanie Marque-Juillet  4 , Victoria Raggueneau  4 , Jennifer Osman  4 , Marc Spentchian  4 , Sophie Rigaudeau  1 , Philippe Rousselot  1 , Caroline Besson  5
Affiliations

A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia

Milena Kohn et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Time interval between the first vaccine injection and the last (if prior to vaccination) or first (if afer vaccination) anti-CD20 administration. Time is represented by vertical bars and the color code represents patients’ serological status. Patients who had their last anti-CD20 administration before their first vaccine injection are represented at the left hand side of the vertical dotted line. Patients who had their last anti-CD20 administration after their first vaccine injection are represented at the right hand side of the vertical dotted line. The color code of the vertical bars represents patients’ serological status. The total number of vaccine doses received prior to serology is represented by colored points (2 doses or 3 doses).
Figure 2.
Figure 2.
Anti-spike titers with respect to anti-CD20 treatment and the number of vaccine injections. The natural logarithm of the anti-spike titer is represented with respect to anti-CD20 treatment status. Red: patients without a history of anti-CD20 treatment or patients who had their last administration more than 1 year prior to the first vaccine injection; green: patients who had their last anti-CD20 administration within 1 year prior to the first vaccine injection; and (blue) patients who had their first vaccine injection prior to their first anti-CD20 administration.
See this image and copyright information in PMC

Comment in

References

    1. Duléry R, Lamure S, Delord M, et al. . Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am J Hematol. 2021;96(8):934-944. - PMC - PubMed
    1. Mato AR, Roeker LE, Lamanna N, et al. . Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136(10):1134-1143. - PMC - PubMed
    1. Herishanu Y, Avivi I, Aharon A, et al. . Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137(23):3165-3173. - PMC - PubMed
    1. Benjamini O, Rokach L, Itchaki G, et al. . Safety and efficacy of BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Haematologica. 2022;107(3):625-634. - PMC - PubMed
    1. Gurion R, Rozovski U, Itchaki G, et al. . Humoral serologic response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD20 antibodies. Haematologica. 2022;107(3):715-720. - PMC - PubMed

MeSH terms